Scientists are hoping to instigate clinical trials for an Alzheimer’s disease vaccine after successful laboratory tests.
Vaccines developed in Australia and California, USA, has shown success in bigenic mice models, the researchers reported.
The scientists at Flinders University, South Australia, have used MultiTEP technology to develop two vaccines, which have worked well on animals with beta-amyloid plaques and tangles composed of hyperphosphorylated tau.
The technology aims to activate a range of T-cells.
The researchers suggest the vaccines might work in a large number of human patients with major histocompatibility complex class II gene polymorphisms.
The lead developer Professor Nikolai Petrovsky is now to spend time in the USA helping to develop clinical trials, which, the researchers say, could begin in two years.
He said: "Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay Alzheimer’s disease progression in the rising number of people around the world."
Testing a MultiTEP-based combination vaccine to reduce A? and tau pathology in Tau22/5xFAD bigenic mice. Alzheimer’s Research & Therapy 17 December 2019; doi: 10.1186/s13195-019-0556-2
Leave a Reply